Navigation Links
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
Date:11/10/2008

ically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. R7128 has shown in vitro activity against all of the most common HCV genotypes (1, 2, 3 and 4).

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with PEGASYS(R) plus COPEGUS(R). Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About R7227 (ITMN-191)

R7227 is an inhibitor of HCV NS3/4A protease activity, and has produced multi-log10 reductions in circulating HCV RNA in chronic HCV patients when administered for 14 days as monotherapy. In support of clinical studies that will combine R7227 with R7128, including the INFORM-1 study, InterMune, Roche and Pharmasset have investigated in vitro the combined antiviral effect of these compounds.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes t
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
2. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
3. InterMune Announces Progress on Pirfenidone in IPF
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
6. InterMune Announces Start of Phase 1b Trial of ITMN-191
7. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
8. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
10. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Sept. 18, 2014  Casen Buswell has a rare vascular ... harden.  His case is one of only 14 known cases ... only hospital in the United States , ... treatment with the dual wave-length laser, is Methodist Children,s Hospital, ... . Using a laser available in South ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... for innovation, increasing clinical development costs, new technologies ... fast-changing environment are important factors driving industry change. ... trial costs continue to rise due to a ... conducted by industry think tanks suggest each day ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin ... peer-reviewed scientific journal Diabetes, Obesity and Metabolism ... Oral-lyn™, the Company,s proprietary buccal insulin spray product. ... subjects with impaired glucose tolerance: the prevoral study , ...
... Bionovo, Inc. (Nasdaq: BNVI ), a pharmaceutical company ... women,s health and cancer, today announced that it had received ... Clinical Guidance meeting that took place on November 8, 2010. ... overall clinical development plan. "We had a ...
Cached Medicine Technology:Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 2Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 3Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 4Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 5Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4
(Date:9/19/2014)... 19, 2014 Ticket Down is ... for his 2014 concert tour. Concertgoers can add promo/coupon ... there are a handful of artists that are considered royalty. ... Saginaw, MichIgan, Wonder has been a force in the music ... the music business, he has released 23 studio albums, three ...
(Date:9/19/2014)... 2014 Business Insider Australia Rates Appy ... Earlier this month Appy Pie was also listed as one ... App Developer' by Yahoo . , Appy Pie a leading ... beautiful applications within minutes and it requires no coding knowledge ... support for latest mobile operating systems, the apps created using ...
(Date:9/19/2014)... Dr. John Paul Gallardo and Dr. William P. ... practice. Routinely at the forefront of cutting-edge oral ... one of the first dentistry teams in the country ... treating periodontal disease. , Periodontal disease ... in the world. The United State’s Surgeon General’s ...
(Date:9/19/2014)... Kyrgyzstan has one of the highest ... the burden of tuberculosis (TB) and address the ... Abt Associates has been awarded the U.S. Agency ... a five-year cooperative agreement with total funding of ... and equitable access to high-quality TB services for ...
(Date:9/19/2014)... Steven Reinberg HealthDay Reporter ... half of all Americans got a flu shot last year, ... months and older get vaccinated for the coming flu season. ... getting the protection from flu they could get," said Dr. ... and Prevention, during a morning news conference. The result ...
Breaking Medicine News(10 mins):Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 2Health News:Stevie Wonder Tickets: Ticket Down Slashes Ticket Prices in Seattle, Boston, New York, Atlanta, Chicago, Detroit, Philadelphia, Toronto, Las Vegas & Oakland 3Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 2Health News:Gallardo & Lamas Periodontics & Implant Dentistry Therapeutic Periodontal Treatment Shown to Improve Patient’s Overall Health 3Health News:New Project Aims to Reduce Burden of Tuberculosis in the Kyrgyz Republic 2Health News:Almost Everyone Needs a Flu Shot: CDC 2Health News:Almost Everyone Needs a Flu Shot: CDC 3
... their advice can have, experts say , WEDNESDAY, Jan. 9 ... about drinking may help at least one in six problem ... a new data review finds. , The systematic review of ... the American Journal of Preventive Medicine . , ...
... screening for cardiovascular problems , , WEDNESDAY, Jan. 9 (HealthDay ... heartbeat pattern in young athletes that makes some of ... , The report comes amid intense debate in the ... said Dr. Mark S. Link, director of the Tufts-New ...
... pieces of ribonucleic acid (RNA) that suppress the spread ... new research shows that the most invasive and aggressive ... molecules. When the researchers put those molecules back into ... their ability to spread., The tiny RNAs prevent the ...
... since you made that New Years resolution to exercise more, but ... , You know all the benefits of a healthy lifestyle: ... exercise has been linked to reduced depressive symptoms and reduced risk ... and watching TV instead of going for a short jog is ...
... HealthCentral,Network, Inc. (http://www.HealthCentral.com ) today announced ... joining the,StopSmokingConnection.com community as an expert. Martin, ... Your Battle Over Shortness of Breath and,web ... write,primarily about Chronic Obstructive Pulmonary Disease (COPD)., ...
... Texas Mutual Insurance Company, an,aggressive tort reform advocate in ... litigation in which the insurance company tried,to overturn an ... a workplace injury,a Dallas state district judge ruled today., ... medical record,Texas Mutual had no evidence to continue to ...
Cached Medicine News:Health News:Short Chat With Doc Can Curb Problem Drinking 2Health News:Test Finds Rare Heart Defect in Some Young Athletes 2Health News:Test Finds Rare Heart Defect in Some Young Athletes 3Health News:Small RNAs can prevent spread of breast cancer 2Health News:Small RNAs can prevent spread of breast cancer 3Health News:Small RNAs can prevent spread of breast cancer 4Health News:Exercising judgment: The psychology of fitness 2Health News:Exercising judgment: The psychology of fitness 3Health News:Exercising judgment: The psychology of fitness 4Health News:Exercising judgment: The psychology of fitness 5Health News:Exercising judgment: The psychology of fitness 6Health News:Exercising judgment: The psychology of fitness 7Health News:Exercising judgment: The psychology of fitness 8Health News:Exercising judgment: The psychology of fitness 9Health News:Exercising judgment: The psychology of fitness 10Health News:Prominent Respiratory Therapist and Author Joins StopSmokingConnection.com as a COPD Expert 2Health News:Judge Rules Texas Mutual Insurance Co. Committed Litigation Fraud With Falsified Document, According to Doyle Raizner LLP 2
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... is a point-of-care system designed for the ... to as Platelet Rich Plasma - PRP) ... small sample of blood. The Symphony II ... which are found in the platelets. The ...
... the introduction of the Leica Dual Imaging Color ... latest available information technology. All important and necessary ... Leica M520 / M500 N optical platform on ... a huge amount of benefits: highest brightness, contrast ...
... Headlight mounted micro video camera has been ... in areas otherwise invisible to all but ... The system may be used for all ... crowding of the sterile area and enabling ...
Medicine Products: